Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Michael Wysota, Marina Konopleva, Shane Mitchell
Current Oncology Reports (2024) Vol. 26, Iss. 4, pp. 409-420
Open Access | Times Cited: 12

Showing 12 citing articles:

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins
Eilyn R. Lacy, Rupesh Nanjunda, Scott L. Klakamp, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
Uwe Platzbecker, Richard A. Larson, Sandeep Gurbuxani
HemaSphere (2025) Vol. 9, Iss. 2
Open Access
Discovery of 5-imidazole-3-methylbenz[d]isoxazole derivatives as potent and selective CBP/p300 bromodomain inhibitors for the treatment of acute myeloid leukemia
Jiankang Hu, Xin Tang, Guolong Luo, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
Upregulation of LSP1 in AML cells enhances AML resistance to sorafenib and promotes apoptosis in CD8+ T cells
Peng Xu, Qiuhui Jiang, Shanlin Fu, et al.
International Immunopharmacology (2025) Vol. 150, pp. 114255-114255
Closed Access
A rapid and green analytical strategy to determine menin inhibitor revumenib in human blood serum via CE-DAD
Sergio Fernández-Trujillo, Gregorio Castañeda, Juana Rodrı́guez, et al.
Microchemical Journal (2025), pp. 113119-113119
Closed Access
RAB39B: A novel biomarker for acute myeloid leukemia identified via multi-omics and functional validation
Shuo Chen, Mengxing Li, Jishi Wang
Open Medicine (2025) Vol. 20, Iss. 1
Open Access
The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies
Daniel J. Chandra, Bernhard Alber, Jennifer N. Saultz
Cancers (2024) Vol. 16, Iss. 15, pp. 2615-2615
Open Access | Times Cited: 3
Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co‐expression network analysis
Haijun Han, Jie Liu, Shengyu Zhu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 14
Open Access | Times Cited: 1
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 1
Single-cell transcriptomics reveals heterogeneity and prognostic markers of myeloid precursor cells in acute myeloid leukemia
Guanghua He, Lai Jiang, Xuancheng Zhou, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?
Caterina Alati, Martina Pitea, Maria Caterina Micò, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 8, pp. 515-525
Closed Access
Unveiling the Role of New Molecules in Acute Myeloid Leukemia: Insights into Disease Pathogenesis and Therapeutic Potential
Diana Martinez, Nicole Santoro, Annalisa Paviglianiti
Targets (2024) Vol. 2, Iss. 4, pp. 396-427
Open Access
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Pasquale Niscola, Nélida I. Noguera, Valentina Gianfelici, et al.
(2024)
Open Access
Page 1

Scroll to top